Drug Trial Radar · NCT05887908
Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
614
Actual
Start
May 23, 2023
Primary completion
Nov 22, 2024
Study completion Nov 26, 2024
Sponsor
- Lead sponsor
- Meiji Seika Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP).
Conditions
- Complicated Urinary Tract Infection
- Acute Pyelonephritis
- cUTI
- AP
Interventions
co-administration of cefepime and nacubactamDrug
2 g cefepime and 1 g nacubactam
co-administration of aztreonam and nacubactamDrug
2 g aztreonama and 1 g nacubactam
imipenem/cilastatinDrug
1 g imipenem/1 g cilastatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT) PopulationTime frame: TOC (Test of Cure visit): 7 [±2] days after EOT (end of treatment) [Day 10 to 23 after the start of treatment]
Locations
61 sites in 9 countries. Site status is shown where the registry gives one.
Meiji Research Site
Pleven, Bulgaria
Meiji Research Site
Rousse, Bulgaria
Meiji Research Site
Silistra, Bulgaria
Meiji Research Site
Sofia, Bulgaria
Meiji Research Site
Beijing, China
Meiji Research Site
Changchun, China
Meiji Research Site
Chongqing, China
Meiji Research Site
Fuyang, China
Meiji Research Site
Ganzhou, China
Meiji Research Site
Huaian, China
Meiji Research Site
Huzhou, China
Meiji Research Site
Nanchang, China
Meiji Research Site
Nanning, China
Meiji Research Site
Quanzhou, China
Meiji Research Site
Shanghai, China
Meiji Research Site
Shantou, China
Meiji Research Site
Shijiazhuang, China
Meiji Research Site
Taian, China
Meiji Research Site
Tianjin, China
Meiji Research Site
Xuancheng, China
Meiji Research Site
Yunnan, China
Meiji Research Site
Zhejiang, China
Meiji Research Site
Zhengzhou, China
Meiji Research Site
Hradec Králové, Czechia
Meiji Research Site
Liberec, Czechia
Meiji Research Site
Prague, Czechia
Meiji Research Site
Ústí nad Labem, Czechia
Meiji Research Site
Kohtla-Järve, Estonia
Meiji Research Site
Tallinn, Estonia
Meiji Research Site
Tartu, Estonia
Meiji Research Site
Meegomäe, Võrumaa, Estonia
Meiji Research Site
Kutaisi, Georgia
Meiji Research Site
Rustavi, Georgia
Meiji Research Site
Tbilisi, Georgia
Meiji Research Site
Fukuyama, Japan
Meiji Research Site
Gifu, Japan
Meiji Research Site
Ibaraki-Town, Higashiibaraki-County, Japan
Meiji Research Site
Iwakuni, Japan
Meiji Research Site
Kanazawa, Japan
Meiji Research Site
Kawachi-Nagano, Japan
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.